Why the study?
CYP2C19*17 is associated with clinical outcomes of drugs metabolized by CYP2C19, but a reliable and simple method to detect this polymorphism was needed.
T-ARMS-PCR provides a highly accurate, low-cost, and simple method for detecting the CYP2C19*17 polymorphism, which is relevant for the metabolism of certain cardiovascular drugs.
Supports T-ARMS-PCR for CYP2C19*17 genotyping; leaves open clinical adoption in cardiovascular pharmacotherapy.
BACKGROUND: CYP2C19*17 (rs12248560) is a functional single nucleotide polymorphism (SNP) in the CYP2C19 gene. It has been shown that CYP2C19*17 is associated with the clinical outcome of some drugs metabolized by CYP2C19 and a decreased risk of some diseases. The aim of this study was to develop a reliable and simple method to detect this polymorphism. METHODS: Tetra-primer amplification refractory mutation system-polymerase chain reaction (T-ARMS-PCR) was used to detect the CYP2C19*17 polymorphism. A total of 93 samples were screened by this method, and the results of T-ARMS-PCR were validated by DNA sequencing. RESULTS: There were 91 samples with the CC genotype (97.8%) and two samples with the CT genotype (2.2%). The frequency of the C allele was 98.9%, and the frequency of the T allele was 1.1%. The DNA sequencing results were completely concordant with the T-ARMS-PCR results. CONCLUSION: T-ARMS-PCR can detect the CYP2C19*17 polymorphism with high accuracy, low costs, and a simple process.
No takes yet. Share an insight, caveat, or question.
Jin et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: